Aclidinium Bromide

CHEMBL551466 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
564.6 g/mol
LogP
Phase
4

The bromide salt form of aclidinium, a long-acting inhaled bronchodilator used for the ongoing management of COPD. It is administered via a dry powder inhaler twice daily and works by keeping the airways relaxed throughout the day and night. Patients should continue to carry a short-acting rescue inhaler for sudden breathing difficulties.

分子量

564.6000 g/mol

TPSA

112.00 Ų

治療領域

作用機序

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-]

InChI

InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1

Molecular Formula

C26H30BrNO4S2

HBD / HBA

1 / 7

回転可能結合数

10

重原子数

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The bromide salt form of aclidinium, a long-acting inhaled bronchodilator used for the ongoing management of COPD. It is administered via a dry powder inhaler twice daily and works by keeping the airways relaxed throughout the day and night. Patients should continue to carry a short-acting rescue inhaler for sudden breathing difficulties.

Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.

Yes, Aclidinium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL551466. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11519741. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.